No beneficial effect of resveratrol in fatty acid oxidation disorders

Resveratrol has been studied in a randomized, placebo-controlled, cross-over clinical trial. Organized jointly by French, Danish and Dutch, the study aimed to measure possible positive effects in several fatty acid oxidation disorders, some of which have muscle expression (carnitine palmitoyltransferase type II or CPTII deficiency):

• eight patients participated in the study, which took place over twenty weeks (8 weeks of treatment or placeboLe placebo est un produit dont la présentation est identique à celle d’un médicament, mais qui ne contient pas de principe actif. Dans un essai clinique, un placebo est utilisé pour mesurer l’action réelle du médicament testé, en comparant les effets du médicament testé contenant le principe actif et ceux du placebo., 4 weeks of wash-out, and 8 weeks of cross-over),
• no change was noted in physical performance at the end of the test,
• the energy profile, in particular that of fatty acids, was not modified.

Accordingly, the authors do not recommend the prescription of this drug.

No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial. Storgaard JH, Løkken N, Madsen KL, et al. J Inherit Metab Dis. 2022 Jan 23.